Look­ing to leave Zol­gens­ma da­ta ma­nip­u­la­tion scan­dal be­hind, Bri­an Kas­par emerges at a new gene ther­a­py play­er

A year af­ter get­ting blamed by No­var­tis for a da­ta ma­nip­u­la­tion scan­dal over its cost­ly gene ther­a­py Zol­gens­ma, Bri­an Kas­par has turned up on the sci­en­tif­ic ad­vi­so­ry board of a new gene ther­a­py play­er.

Kas­par and Thomas Dee, an old AveX­is bud­dy, are tak­ing board roles at End­sulin, a small biotech found­ed by long­time Uni­ver­si­ty of Wis­con­sin sur­geon Hans Sollinger that’s search­ing for a bet­ter treat­ment for type 1 di­a­betes — one that doesn’t in­volve in­sulin jabs or a pan­creas trans­plant.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER